Targeted Drug Delivery for Challenging Oncology Therapeutics
NanoCage Bio is developing a protein nanocage platform designed to improve the delivery, targeting, and efficacy of therapeutic candidates while reducing off-target toxicity.
Drug Delivery Limits the Potential of Oncology Therapeutics
Many promising cancer therapeutics fail not because they lack activity, but because they cannot be effectively delivered to the right place in the body.
Key challenges include:
Poor targeting to tumour cells
Degradation before reaching the site of action
Extremely low accumulation in solid tumours
Off-target toxicity and side effects
In fact, less than 1% of administered nanoparticles typically reach solid tumours, significantly limiting therapeutic impact.
These challenges lead to failed or underperforming drug candidates, increasing cost and slowing progress in oncology.
Advanced Instruments
Laboratory Specialists
Neurological Analysis
A Smarter Approach to Drug Delivery
Many promising therapeutics are limited not by their potential, but by how effectively they can be delivered. Improving delivery is key to unlocking better outcomes in oncology.
A Protein Nanocage Platform for Targeted Delivery
NanoCage Bio is developing a drug delivery platform designed to improve how therapeutics are formulated, delivered, and released.
Our approach focuses on:
Analytical Projects
Dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor.
Strict Quality Practices
Dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor.
Complete Blood Count
Dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor.
Customized Solutions
Dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor.
Advanced Instruments
Dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor.
Get in Touch
We are currently exploring how this technology could be applied to real-world drug development challenges.
If you are working on oncology therapeutics and are interested in improving delivery, targeting, or efficacy, we would welcome a conversation.
Contact Details
Dr Antonia Molloy
📧 antonia.molloy@nottingham.ac.uk